Search PubMed⌕ Search

Biomedical subjects

B J Manaster

Publications and source records attributed to B J Manaster.

At least 55 records · Page 3Linked to original sources
PubMed1997

Cementless femoral revision arthroplasty. 2- to 5-year results with a modular titanium alloy stem.

Seventy-five consecutive cementless femoral revision arthroplasties were performed, using a modular titanium alloy stem (S-ROM, Joint Medical Products, Stamford, CT). Sixty-six hips were available for complete follow-up evaluation at 2 to 5 years (average, 3.4 years). Independent clinical analysis compared pre- with postoperative modified Harris hip scores and examined patient satisfaction. Independent radiographic analysis was also undertaken. There were two rerevisions, both for hematogenous sepsis. Of the rest, clinical scores improved from a preoperative value of 44 to a postoperative value of 83. Eighty-nine percent of patients were satisfied or very satisfied with the results of surgery. Fifty-two stems had solid bony ingrowth, seven were stabilized by fibrous tissue, and five were radiographically loose. Five-year survival, with rerevision as endpoint, was 96.4%.

Adult↗
PubMed1996

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study.

OBJECTIVE: To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active ankylosing spondylitis (AS) that is not controlled with nonsteroidal antiinflammatory drug therapy. METHODS: Two hundred sixty-four patients with AS were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on morning stiffness, back pain, and physician and patient global assessments. RESULTS: While longitudinal analysis revealed a trend favoring SSZ in the middle of treatment, no difference was seen at the end of treatment. Response rates were 38.2% for SSZ and 36.1% for placebo (P = 0.73). The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). AS patients with associated peripheral arthritis showed improvement that favored SSZ (P = 0.02). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. CONCLUSION: SSZ at a dosage of 2,000 mg/day does not seem to be more effective than placebo in the treatment of AS patients with chronic, longstanding disease. SSZ is well tolerated and may be more effective than placebo in the treatment of AS patients with peripheral joint involvement. This effect is more pronounced in treatment of the peripheral arthritis in this subgroup of AS patients.

Adult↗
PubMed1996

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.

OBJECTIVE: To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective for the treatment of active psoriatic arthritis (PsA) resistant to nonsteroidal antiinflammatory drug therapy. METHODS: Two hundred twenty-one patients with PsA were recruited from 15 clinics, randomized (double-blind) to SSZ or placebo treatment, and followed up for 36 weeks. Treatment response was based on joint pain/ tenderness and swelling scores and physician and patient global assessments. RESULTS: Longitudinal analysis revealed a trend favoring SSZ treatment (P = 0.13). At the end of treatment, response rates were 57.8% for SSZ compared with 44.6% for placebo (P = 0.05). The Westergren erythrocyte sedimentation rate declined more in the PsA patients taking SSZ than in those taking placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea. CONCLUSION: SSZ at a dosage of 2,000 mg/day is well tolerated and may be more effective than placebo in the treatment of patients with PsA.

Adult↗
PubMed1996

Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study.

OBJECTIVE: To determine whether sulfasalazine (SSZ) at a dosage of 2,000 mg/day is effective in the treatment of reactive arthritis (ReA) that has been unresponsive to nonsteroidal antiinflammatory drug (NSAID) therapy. METHODS: One hundred thirty-four patients with ReA who had failed to respond to NSAIDs were recruited from 19 clinics, randomized (double-blind) to receive either SSZ or placebo, and followed up for 36 weeks. The definition of treatment response was based on joint pain/tenderness and swelling scores and physician and patient global assessments. RESULTS: Longitudinal analysis revealed improvement in the patients taking SSZ compared with those taking placebo, which appeared at 4 weeks and continued through the trial (P = 0.02). At the end of treatment, response rates were 62.3% for SSZ treatment compared with 47.7% for placebo treatment. The Westergren erythrocyte sedimentation rate declined more with SSZ treatment than with placebo (P < 0.0001). Adverse reactions were fewer than expected and were mainly due to nonspecific gastrointestinal complaints. CONCLUSION: SSZ at a dosage of 2,000 mg/day is well tolerated and effective in patients with chronically active ReA.

Adult↗
PubMed1996

Justification for decreasing the number of views taken in radiologic follow-up of Casper plate cervical spine hardware.

RATIONALE AND OBJECTIVES: We tested the null hypothesis that there would be no difference between the diagnostic yield of the lateral radiograph alone and the yield of the lateral and anteroposterior views combined when assessing patients after placement of an anterior cervical appliance. METHODS: We evaluated 630 radiographic examinations obtained from 117 consecutive patients who had anterior cervical plating. For each examination, we looked at the lateral radiograph first and then at the anteroposterior radiography to determine whether there would be any additional information on the anteroposterior film. RESULTS: Of 501 examinations in which the lateral and anteroposterior views were available, we found that the anteroposterior view added information in 18. In eight of the 18, the added information consisted only of clinically insignificant tilting of the plate. Significant findings were seen in 209 examinations in the lateral view and in 219 examinations with the lateral and anteroposterior views combined. This was not significantly different. CONCLUSION: The anteroposterior view rarely adds significant information. It probably should be obtained early postoperatively to check for tilting of the plate but after that only for specific indications. This will save money and reduce the patient's exposure to radiation.

Adolescent↗
PubMed1996

From the RSNA refresher courses. Total hip arthroplasty: radiographic evaluation.

Expected appearances of total hip arthroplasty vary according to type of implant, its method of fixation (cemented, porous coating for bone ingrowth, press fit), and whether it is a revision. Cemented arthroplastic components normally may show 1-2-mm-wide radiolucent zones at cement interfaces. Definite loosening is diagnosed when progressive widening of the radiolucent zone, migration of a cemented component, or change in alignment is seen. In cementless arthroplasty, normal findings include calcar resorption, radiolucent zones up to 2 mm in width, cortical thickening, periosteal reaction, endosteal sclerosis, and even subsidence of the femoral component that stabilizes at less than 1 cm. The most reliable radiographic signs of loosening in cementless arthroplasty are progressive subsidence, migration, or tilt of the component. Because subsidence or change in alignment may be very subtle, serial radiography and measurement are often required for diagnosis. Other signs that indicate loosening include bead shedding (in porous-coated prostheses), extensive cortical hypertrophy, endosteal bone bridging at the stem tip, endosteal scalloping, and a radiolucent zone wider than 2 mm. In revision arthroplasty, wide radiolucent zones and subsidence are common. The diagnosis of revision failure is based on progressive widening of the radiolucent zones and change in component position after 12 months.

Hip Joint↗
PubMed1995

Total knee arthroplasty: postoperative radiologic findings.

The first generation of total knee arthroplasties had unacceptably high failure rates due to prosthetic design problems. The current generation, known generically as total condylar arthroplasties, closely duplicates the normal anatomy, motion, and stability of the knee. They combine adequate flexion with 15-20 degrees of rotation and 5-10 degrees of medial-lateral motion. These knees have a 90% success rate over 10 years, whether cemented or uncemented [1]. This essay is designed to describe the normal imaging appearance and radiographic findings in complications of these prostheses.

Aged↗
PubMed1993

Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis.

OBJECTIVE: To define clinical and laboratory outcomes of longterm recombinant interferon-gamma (rIFN-gamma) treatment of patients with rheumatoid arthritis (RA). METHODS: Patients with RA (70) completing a 12-week multicenter double blind trial comparing rIFN-gamma with placebo were enrolled in a longterm prospective protocol evaluating rIFN-gamma in RA. RESULTS: The majority of patients sustained clinical improvement for one year. Eight (11%) patients with RA continued to receive rIFN-gamma after 5 years. One patient fulfilled remission criteria. rIFN-gamma was well tolerated with remarkably few suspected adverse drug reactions. Forty-seven (67%) patients discontinued rIFN-gamma because of lack of efficacy, 7 (10%) because of concurrent illnesses, 5 (7%) were not compliant to study protocol, 3 (4%) developed suspected adverse drug reactions for a total of 62 (89%) withdrawals over the 5 years of followup. Patients continuing rIFN-gamma treatment for 5 years had lower initial total leukocyte and neutrophil counts and higher hemoglobin and hematocrit levels than patients who discontinued rIFN-gamma during the 5-year followup. CONCLUSIONS: Longterm treatment of RA with rIFN-gamma was generally well tolerated. Although many patients maintained sustained clinical improvement for at least one year, the main reason for discontinuing the drug over 5 years was the lack of continued benefit.

Arthritis, Rheumatoid↗
PubMed1993

Giant cell tumors of bone.

Giant cell tumor is a lesion that usually presents with a radiographically characteristic appearance in a predictable location and patient population. It has a few rare presentations such as pulmonary metastases and multifocal lesions. Prognosis of ultimate tumor behavior is dependent on surgical staging (which requires careful radiographic analysis to detect cortical breakthrough and joint involvement) and type of treatment. The recurrence rate is relatively high with simple curettage but decreases with adjuvant treatment at the tumor site. Optimal therapy for the more aggressive lesions is wide resection, but compromise is frequently required when such a resection would sacrifice joint function because of the subarticular location of the giant cell tumor. Radiation therapy is reserved for surgically inaccessible or otherwise inoperable lesions because of a relatively poor radiosensitivity and concerns about induction of high grade sarcomas. Radiographic follow-up evaluation for recurrence is recommended for approximately 5 years but may be difficult to interpret in individual patients because of an overlap in the appearance of healing and recurrence.

Bone Neoplasms↗
PubMed1991

Musculoskeletal oncologic imaging.

A cost efficient algorithm is presented for workup of musculoskeletal tumors. This is given within the framework of requirements for surgical staging. Considerations regarding both percutaneous and open biopsy are outlined. The advantages as well as limitations of MR imaging are stressed.

Algorithms↗